Abrogation of Immune Effector Cell Neurotoxicity Syndrome (ICANS) By Rimiducid (RIM) in Patients Treated with CD19-Specific Chimeric Antigen Receptor Modified T-Cells (CAR-T) Engineered with an Inducible Caspase 9 (iC9 CAR.19)-Clinical and Pharmacodynamic Correlates
Year: 2022
Type: article
Source: Blood
Authors: Matthew C. Foster, Barbara Savoldo, Winnie Lau, Clio Rubinos, Natalie S. Grover, Paul M. Armistead, James M. Coghill, Katarzyna Joanna Jamieson, Robert Hagan, J. Kaitlin Morrison, Faith Brianne Buchanan, Catherine Joyce Arago Cheng, Anastasia Ivanova, Tammy Cavallo, John West, Megan Gonzalez, Jonathan S. Serody, Gianpietro Dotti
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4310107736